# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants

> **NCT02209506** · PHASE1 · TERMINATED · sponsor: **Takeda** · enrollment: 23 (actual)

## Conditions studied

- Safety
- Tolerability
- Pharmacokinetics
- Pharmacodynamics

## Interventions

- **DRUG:** MLN3126
- **DRUG:** MLN3126 Matched Placebo

## Key facts

- **NCT ID:** NCT02209506
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Long-term animal toxicology findings (see detailed description).
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209506, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02209506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*